- Aastrom Biosciences (ASTM +30.1%) acquires Sanofi's Cell Therapy and Regenerative Medicine business for $6.5M.
- Current revenue for the business is $44M driven by Carticel (autologous cultured chondrocytes), Epicel (cultured epidermal autografts) and MACI (matrix-induced autologous chondrocyte implant).
- Sanofi acquired the business when it bought Genzyme several years ago.
- (SNY)
Aastrom buys Sanofi unit
Recommended For You
About VCEL Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| VCEL | - | - |
| Vericel Corporation | ||